Ratings Alkem Laboratories Limited

Equities

ALKEM

INE540L01014

Market Closed - NSE India S.E. 07:43:48 2024-07-15 am EDT 5-day change 1st Jan Change
5,384 INR +3.56% Intraday chart for Alkem Laboratories Limited +6.32% +3.48%

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • The company's profit outlook over the next few years is a strong asset.
  • The group's high margin levels account for strong profits.
  • The company is in a robust financial situation considering its net cash and margin position.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

  • With an expected P/E ratio at 35.16 and 30.07 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's enterprise value to sales, at 4.84 times its current sales, is high.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.
  • The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
+3.48% 7.44B
C-
+63.39% 854B
C+
+39.42% 636B
B
-4.61% 361B
C+
+16.97% 324B
B-
+8.41% 301B
C+
+14.19% 247B
B+
+5.81% 230B
A+
+16.77% 228B
B-
+14.17% 177B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. ALKEM Stock
  4. Ratings Alkem Laboratories Limited